Alimera Sciences, Inc. (NASDAQ:ALIM) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM - Free Report) by 61.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,045,460 shares of the biopharmaceutical company's stock after buying an additional 396,506 shares during the quarter. Vanguard Group Inc. owned about 2.00% of Alimera Sciences worth $4,077,000 as of its most recent SEC filing.

Separately, Fifth Lane Capital LP purchased a new position in Alimera Sciences during the 1st quarter valued at approximately $83,000. Institutional investors and hedge funds own 99.83% of the company's stock.

Alimera Sciences Trading Up 0.2 %

Shares of NASDAQ:ALIM traded up $0.01 during trading on Monday, hitting $5.59. The company had a trading volume of 162,796 shares, compared to its average volume of 206,875. The stock has a market cap of $292.85 million, a price-to-earnings ratio of -3.55 and a beta of 1.28. Alimera Sciences, Inc. has a one year low of $2.61 and a one year high of $5.65. The company has a fifty day simple moving average of $5.06 and a two-hundred day simple moving average of $4.10. The company has a debt-to-equity ratio of 1.71, a current ratio of 2.62 and a quick ratio of 2.51.

Alimera Sciences (NASDAQ:ALIM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. The business had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.76 million. As a group, equities analysts forecast that Alimera Sciences, Inc. will post -0.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Maxim Group restated a "hold" rating on shares of Alimera Sciences in a report on Tuesday, June 25th. StockNews.com started coverage on Alimera Sciences in a research note on Tuesday, August 13th. They issued a "hold" rating for the company. Alliance Global Partners reaffirmed a "neutral" rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, HC Wainwright lowered Alimera Sciences from a "buy" rating to a "neutral" rating and set a $6.00 price objective for the company. in a research note on Tuesday, June 25th.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).